Showing results (521-530 of 1,837) with videos related to

Sort By:
Pageof 184
ESMO Open|April 12, 2018
Four distinct immune microenvironment subtypes in gastric adenocarcinoma with special reference to microsatellite instabilityJunhun Cho, Young Hwan Chang, You Jeong Heo, et al.
ESMO Open|April 12, 2018
Relevance of a molecular tumour board (MTB) for patients' enrolment in clinical trials: experience of the Institut CurieClémence Basse, Claire Morel, Marie Alt, et al.
ESMO Open|July 19, 2018
Postoperative chemotherapy with single-agent fluoropyrimidines after resection of colorectal cancer liver metastases: a meta-analysis of randomised trialsDavide Mauri, George Zarkavelis, Panagiotis Filis, et al.
ESMO Open|July 19, 2018
Patient-reported outcomes in a phase II, North American study of alectinib in patients with ALK-positive, crizotinib-resistant, non-small cell lung cancerSai-Hong Ignatius Ou, Mark A Socinski, Shirish Gadgeel, et al.
ESMO Open|June 27, 2018
Single-agent PARP inhibitors for the treatment of patients with BRCA-mutated HER2-negative metastatic breast cancer: a systematic review and meta-analysisFrancesca Poggio, Marco Bruzzone, Marcello Ceppi, et al.
ESMO Open|June 27, 2018
Practical issues of biomarker-assisted targeted therapy in precision medicine and immuno-oncology eraDae Ho Lee
ESMO Open|August 26, 2020
How I treat adverse effects of CAR-T cell therapyLucrecia Yáñez, Ana Alarcón, Miriam Sánchez-Escamilla, et al.
ESMO Open|April 5, 2023
A randomized controlled trial of hand/foot-cooling by hilotherapy to prevent oxaliplatin-related peripheral neuropathy in patients with malignancies of the digestive systemA Coolbrandt, H Tobback, R Govaerts, et al.
ESMO Open|April 5, 2023
Sex and gender perspectives in colorectal cancerI Baraibar, J Ros, N Saoudi, et al.
ESMO Open|April 7, 2023
A phase II study of pembrolizumab plus carboplatin in BRCA-related metastatic breast cancer (PEMBRACA)L Cortesi, M Venturelli, G Cortesi, et al.
Pageof 184